| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| NRX Pharmaceuticals, Inc. | Interim CEO | Employee Stock Option (Right to buy) | 247,200 | $49,440 | $0.2000 | 16 Aug 2021 | Direct |
| NRX Pharmaceuticals, Inc. | Interim CEO | Common Stock | 23,710 | $7,585 | $0.3199 | 15 Sep 2021 | Direct |
| NRX Pharmaceuticals, Inc. | Interim CEO | Employee Stock Option | 347,200 | 08 Mar 2022 | Direct | ||
| NRX Pharmaceuticals, Inc. | Interim CEO | Restricted Stock Units | 36,290 | 16 Aug 2021 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| NRXP | NRX Pharmaceuticals, Inc. | 08 Mar 2022 | 1 | +$261,000 | 4 | Interim CEO | 10 Mar 2022, 15:04 |
| NRXP | NRX Pharmaceuticals, Inc. | 16 Aug 2021 | 4 | -$477,658 | 4 | Chief Comm. & Patient Officer | 02 Nov 2021, 16:04 |
| NRXP | NRX Pharmaceuticals, Inc. | 24 May 2021 | 2 | $0 | 4 | Chief Comm. & Patient Officer | 10 Jun 2021, 18:44 |
| NRXP | NRX Pharmaceuticals, Inc. | 24 May 2021 | 0 | $0 | 3 | Chief Comm. & Patient Officer | 10 Jun 2021, 18:29 |